Status:

COMPLETED

Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder

Lead Sponsor:

University of California, Los Angeles

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Obsessive-Compulsive Disorder

Eligibility:

All Genders

6-18 years

Phase:

NA

Brief Summary

This study will examine the way cognitive behavioral therapy changes the structure of the brain in patients with obsessive-compulsive disorder and will thereby determine what makes cognitive behaviora...

Detailed Description

Obsessive-compulsive disorder (OCD) afflicts 2% to 4% of children and adolescents, who suffer from persistent, unwanted thoughts and repetitive behaviors. One of the most effective treatments of OCD i...

Eligibility Criteria

Inclusion

  • Meets DSM-IV diagnostic criteria for OCD as primary diagnosis, based on the Anxiety Disorders Interview Schedule (ADIS) Clinical Severity Rating
  • Clinical Global Impressions severity score of at least 4, reflecting moderately ill or worse status
  • Children's Yale-Brown Obsessive Compulsive Scale total score of greater than or equal to 16
  • No medication for OCD or other psychiatric condition in the past 4 weeks and no use of fluoxetine for the past 6 weeks
  • Child is fluent in English
  • Parental informed consent and child or adolescent informed assent forms are signed
  • For females of childbearing potential a negative pregnancy test will be required for study entry

Exclusion

  • IQ of less than 80 on the Wechsler Abbreviated Scales of Intelligence
  • A lifetime DSM-IV diagnosis of pervasive developmental disorder, mania, psychosis, conduct disorder, or substance dependence assessed through ADIS
  • Current DSM-IV diagnosis of major depressive disorder or attention deficit hyperactivity disorder any subtype, assessed through an ADIS rating of 4 or higher
  • Any serious psychiatric, psychosocial, or neurological condition, such as a tic disorder, non-OCD anxiety, aggression, or family discord, that requires immediate treatment other than that provided in the current study
  • One or more failed adequate trials of exposure-based CBT, defined as at least 10 sessions of therapist-assisted, exposure-based CBT with which the patient voluntarily complied
  • More than one failed selective serotonin reuptake inhibitor trial adequate in dose and duration, defined as at least 8 weeks of treatment with at least 20 mg of fluoxetine, 20 mg of paroxetine, 75 mg of sertraline or fluvoxamine, or 75mg of clomipramine
  • Any body metal (other than dental fillings), pregnancy, or other contraindications to MRSI scan

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2016

Estimated Enrollment :

119 Patients enrolled

Trial Details

Trial ID

NCT00748761

Start Date

June 1 2008

End Date

December 31 2016

Last Update

March 25 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA Child Psychiatry

Los Angeles, California, United States, 90024